Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01603017
Other study ID # 06/S0802/131
Secondary ID
Status Completed
Phase N/A
First received May 15, 2012
Last updated May 17, 2012
Start date September 2007
Est. completion date December 2008

Study information

Verified date May 2012
Source NHS Grampian
Contact n/a
Is FDA regulated No
Health authority United Kingdom: National Health Service
Study type Interventional

Clinical Trial Summary

Nuclear Magnetic Resonance Therapy (NMRT) is gaining as a novel mode of therapy in osteoarthrosis. A prospective double blind randomised study of 100 patients was conducted to investigate efficacy of NMRT in the treatment of mild to moderate osteoarthrosis (OA) of the knee joint.

The null hypothesis was that there is no benefit of NMRT over placebo in mild to moderate oteoarthosis of the knee.


Description:

This study was approved by the Regional Ethics Committee. Patients were recruited from referrals made by General Practitioners to a single Orthopaedic Outpatient Department between October 2007 and February 2008. The study was a prospective placebo controlled, double blind randomised mono centric study with a follow up period of 6 months.

All potential trial participants demonstrated symptomatic mild to moderate OA of the knee joint diagnosed by an experienced consultant orthopaedic surgeon. Radiographic evidence was gathered by means of standard clinical standing antero-posterior and lateral radiographs of the knee.

Baseline assessment included :

1. clinical examination

2. active Range of movement

3. plain radiographs

4. WOMAC osteoarthritis index

5. Oxford Knee Score (OKS)

6. Severity of pain VAS.

7. Strength and frequency of any painkillers taken.

8. Phyasiotherapy Study design was directed at use of NMRT in a clinical setting. It was therefore considered valid to not restrict the use of the pain killers and physiotherapy. Positional Magnetic Resonance Imaging (pMRI) scan of the knee joint was undertaken.

Randomisation was carried out by means of visually identical computer chip cards numbered from 1 to 100 which had been independently programmed by the manufacturer. Thus, half of the computer chip cards (n=50) were programmed to activate the magnetic fields (= treatment group) and remaining half (n=50) were programmed not to activate magnetic fields (=placebo group) of the device. The research team and patients were blinded to the programmed activity of the cards. The magnetic resonance indicator LED lamp on the device was disabled by the manufacturer to ensure that the operator and patients were blinded to the therapy status. Every patient entering the study was asked to choose a numbered card from those available, and this card was then used to operate the device for that specific patient for all five sessions of NMRT.

The study used the manufacturer's clinical recommendation for therapy. Patients were subjected to one-hour sessions of NMRT (or placebo) on five consecutive days, giving a total of five hours of NMRT (or placebo). This was given on an outpatient basis.

The device is made up of twelve independently controlled coil systems that are spaced orthogonally. These are designed to produce a 3-dimensional therapy field. Along with a separately generated permanent magnetic field, the 3-dimensional therapy field forms a nuclear resonance field in the center of the coil system. The desired dose of NMRT is achieved with the help of MBSTĀ® - Treatment software, which is controlled by a computer chip card. The device can generate a magnetic field of 3.0 mT (typical) and maximum of 10 mT extending up to 30 cm around the device.

Patients were called for review at 1 week (1w), 1 month (1m), 3 months (3m) and 6 months (6m) when clinical examination, WOMAC osteoarthritis index and OKS were repeated. They were also asked to record VAS and details of painkillers taken during the week before each review. Due to the lack of recognised analgesia equivalencies, the quantity of pain killers taken were graded with reference to the amount and frequency taken at baseline - less than baseline was graded as 1, same as baseline was graded as 2 and more than baseline was graded as 3.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 2008
Est. primary completion date December 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Osteoarthrosis of the knee(s)

- Moderately severe (grade 1-2)

Exclusion Criteria:

- Prior knee surgery

- Implanted metallic devices

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Device:
MRI therapy
5 treatments with magnetic field delivered to knee (n=50)
MRI therapy (off)
5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)

Locations

Country Name City State
United Kingdom Woodend Hospital Aberdeen Scotland

Sponsors (1)

Lead Sponsor Collaborator
NHS Grampian

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Oxford Knee Score Patient administered validated questions 12 weeks No
See also
  Status Clinical Trial Phase
Completed NCT02445898 - Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients Phase 2/Phase 3
Completed NCT02542592 - Effect of Methylprednisolone on Immune Signaling in Hip-arthroplasty Patients Phase 2/Phase 3
Completed NCT02910830 - Osteoarthritis Relationships and Tobacco " Ancillary Study Khoala " N/A
Completed NCT01443975 - Clinical Evaluation on the Use of the X-pander Device N/A
Completed NCT02222740 - A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain Phase 2
Completed NCT00860873 - Effectiveness of Glucosamine + Chondroitin in Osteoarthrosis Phase 3
Recruiting NCT02923310 - Evaluation of Two Types of PRP in Knee Osteoarthritis Phase 1/Phase 2
Active, not recruiting NCT02518269 - A 3-Arm Study on G7 Acetabular Cup With Echo BiMetric Stem in Total Hip Arthroplasty N/A
Completed NCT03093038 - Early Stability of the Delta-TT Cup With Polyethylene Insert Versus a Ceramic Insert. A RSA Study. N/A
Completed NCT02967874 - Autologous Adipose-Derived Stromal Vascular Fraction Cells for Osteoarthritis Treatment Phase 1/Phase 2
Withdrawn NCT02341079 - Intraoperative Liposomal Bupivacaine Injection in Primary Total Knee Arthroplasty Phase 2/Phase 3
Completed NCT00291499 - Efficacy Study of Condrosulf in the Treatment of Symptomatic OA of the Hand Phase 3
Recruiting NCT05882227 - Nursing Intervention for the Reduction of Anxiety During the Process of Primary Total Hip Arthroplasty Within the Optimized Recovery Program. N/A
Completed NCT05697952 - E1K Intra Articular(IA) Treatment for Knee Osteoarthritis Phase 2
Completed NCT01940692 - Topical and Intravenous Administration of TXA Are Equally Effective in DAA THA Phase 2
Completed NCT02071745 - Navigated Total Knee Arthroplasty, the Correlation to CT Scans and Clinical Results N/A
Completed NCT02332616 - Effect of Methylprednisolone on Complement Activation in Patients Undergoing Total Knee-arthroplasty Phase 3
Completed NCT02332629 - Effect of Methylprednisolone on Endothelial Function in Patients Undergoing Total Knee-arthroplasty Phase 3
Completed NCT02319343 - Effect of Methylprednisolone on Quadriceps Muscle Function in Patients Undergoing Total Knee-arthroplasty Phase 3
Completed NCT02332603 - Effect of Methylprednisolone on Glucose Homeostasis in Patients Undergoing Total Hip- and Knee-arthroplasty Phase 3